SLC-Mn-HMNDYT2 Identifying and exploiting SLC39A14 regulatory mechanisms for the future development of therapeutics
- Coordinator
- Medizinische Universitaet Wien, Austria
- Runs
- 1 September 2025 to 31 August 2027
- Status
- Running
- EU funding
- €214k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101212417
What the project is doing
In the project's own words, from its summary on CORDIS.
Solute carriers (SLCs) are membrane proteins that mediate the transport of biological and inorganic molecules. SLC39A14 regulates the transport of manganese (Mn) into primarily liver and intestinal cells from the blood. Bi-allelic loss of function (LOF) variants in SLC39A14 lead to an accumulation of blood Mn, which travels to the brain, causes significant deficits in motor function, eventually leads to the patients being non-ambulatory.
Accordingly, these patients are diagnosed with Hypermanganesaemia with dystonia 2 (HMNDYT2) and are treated with Mn chelating agents. This treatment removes excess Mn from the blood
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Universitaet Wien | Wien | Austria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI